Background
Background Sub-syndromal Sub-syndromal symptoms in bipolar disorder impair symptoms in bipolar disorder impair functioning and diminish quality of life. functioning and diminish quality of life.
Aims Aims To examine factors associated
To examine factors associated with time spent with sub-syndromal with time spent with sub-syndromal symptoms and to characterise how these symptoms and to characterise how these symptoms influence outcomes. symptoms influence outcomes.
Method Method In a double-blind randomised
In a double-blind randomised maintenance trial, patients received either maintenance trial, patients received either olanzapine or lithium monotherapy for1 olanzapine or lithium monotherapy for1 year. Stepwise logistic regression models year. Stepwise logistic regression models were used to identify factors that were were used to identify factors that were significant predictors of percentage time significant predictors of percentage time spent with sub-syndromal symptoms.The spent with sub-syndromal symptoms.The presence of sub-syndromal symptoms presence of sub-syndromal symptoms during the first 8 weeks was examined as a during the first 8 weeks was examined as a predictor of subsequent relapse. predictor of subsequent relapse.
Results

Results Presence of sub-syndromal
Presence of sub-syndromal depressive symptoms during the first depressive symptoms during the first 8 weeks significantly increased the 8 weeks significantly increased the likelihood of depressive relapse (relative likelihood of depressive relapse (relative risk 4.67, risk 4.67, P P5 50.001). Patients with 0.001). Patients with psychotic features and those with a psychotic features and those with a greater number of previous depressive greater number of previous depressive episodes were more likely to experience episodes were more likely to experience sub-syndromal depressive symptoms sub-syndromal depressive symptoms (RR (RR¼2.51, 2.51, P P5 50.001and RR 0.001and RR¼2.35, 2.35, P P¼0.03 respectively).
0.03 respectively).
Conclusions
Conclusions These findings help to These findings help to identify patients at increased risk of identify patients at increased riskof affective relapse and suggestthat affective relapse and suggestthat appropriate therapeutic interventions appropriate therapeutic interventions should be considered even when should be considered even when syndromal-level symptoms are absent. syndromal-level symptoms are absent.
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Recent attention has focused on the need to Recent attention has focused on the need to develop therapeutic strategies that allow develop therapeutic strategies that allow patients with bipolar affective disorder to patients with bipolar affective disorder to return to a premorbid level of function. return to a premorbid level of function. Effective therapies are currently available Effective therapies are currently available for the treatment of acute manic and defor the treatment of acute manic and depressive episodes, and for prolonging time pressive episodes, and for prolonging time in remission. However, patients considered in remission. However, patients considered to have responded to treatment may to have responded to treatment may nevertheless continue to experience subnevertheless continue to experience subsyndromal symptoms that impair functionsyndromal symptoms that impair functioning and diminish quality of life. This disparing and diminish quality of life. This disparity between symptom amelioration and ity between symptom amelioration and functional outcomes among patients with functional outcomes among patients with bipolar disorder has been described by bipolar disorder has been described by Tohen Tohen et al et al (1990 Tohen et al et al ( (1990a and Chengappa ) and Chengappa et al et al (2005) . In a study of first-episode disorder, (2005) . In a study of first-episode disorder, Tohen Tohen et al et al (2000) observed that only 38% (2000) observed that only 38% of patients achieved functional recovery of patients achieved functional recovery within 2 years of treatment for an acute within 2 years of treatment for an acute manic episode. One factor that may manic episode. One factor that may contribute to the difficulty in reaching full contribute to the difficulty in reaching full functional recovery is the presence of subfunctional recovery is the presence of subsyndromal symptoms that either individusyndromal symptoms that either individually or as an aggregate are not sufficiently ally or as an aggregate are not sufficiently severe to constitute a major mood episode, severe to constitute a major mood episode, but interfere with functioning. but interfere with functioning.
A recent reassessment of bipolar-A recent reassessment of bipolarspectrum disorders including patients with spectrum disorders including patients with sub-syndromal symptoms revealed at least sub-syndromal symptoms revealed at least a five-fold greater prevalence than found a five-fold greater prevalence than found with traditionally defined syndromal with traditionally defined syndromal diagnoses (Judd & Akiskal, 2003) . The diagnoses (Judd & Akiskal, 2003) . The persistence of sub-syndromal symptoms in persistence of sub-syndromal symptoms in patients with bipolar disorder has been patients with bipolar disorder has been shown to contribute substantially to funcshown to contribute substantially to functional impairment (Gitlin tional impairment (Gitlin et al et al, 1995; , 1995; Altshuler Altshuler et al et al, 2002) . Furthermore, sub-, 2002) . Furthermore, subsyndromal symptoms are associated with syndromal symptoms are associated with an increased risk of relapse (Goodnick an increased risk of relapse (Goodnick et et al al, 1987; Tohen , 1987; Tohen et al et al, 1990a; Keller , 1990a; Keller et al et al, , 1992) . Keller 1992). Keller et al et al (1992 Keller et al et al ( ) demonstrated (1992 demonstrated that patients prescribed lithium who that patients prescribed lithium who achieved standard serum levels of the drug achieved standard serum levels of the drug were both less likely to develop sub-syndrowere both less likely to develop sub-syndromal symptoms and less likely to experience mal symptoms and less likely to experience relapse relative to those who achieved lowrelapse relative to those who achieved lowrange levels, which highlights the role of range levels, which highlights the role of adequate therapeutic treatment in the manadequate therapeutic treatment in the management of these symptoms. agement of these symptoms.
A critical part of developing effective A critical part of developing effective treatment strategies for the management treatment strategies for the management of both sub-syndromal and syndromal of both sub-syndromal and syndromal symptoms requires a greater understanding symptoms requires a greater understanding of the factors involved in their developof the factors involved in their development. The goal of our ment. The goal of our post hoc post hoc analyses analyses was to identify factors that are associated was to identify factors that are associated with a greater percentage of time with with a greater percentage of time with sub-syndromal symptoms, and to characsub-syndromal symptoms, and to characterise how these symptoms influence terise how these symptoms influence outcomes in a randomised double-blind outcomes in a randomised double-blind clinical trial of relapse prevention comparclinical trial of relapse prevention comparing olanzapine and lithium in patients with ing olanzapine and lithium in patients with bipolar I disorder. bipolar I disorder.
METHOD METHOD
The details of this randomised double-blind The details of this randomised double-blind controlled trial have been described precontrolled trial have been described previously (Tohen viously (Tohen et al et al, 2005) and are sum-, 2005) and are summarised briefly here. Participants were at marised briefly here. Participants were at least 18 years old and met DSM-IV least 18 years old and met DSM-IV (American Psychiatric Association, 1994) (American Psychiatric Association, 1994) criteria for an index manic or mixed bicriteria for an index manic or mixed bipolar I episode based on the Structured polar I episode based on the Structured Clinical Interview for DSM-IV (First Clinical Interview for DSM-IV (First et al et al, , 1995) . Prerequisites for study entry were a 1995). Prerequisites for study entry were a baseline total score of 20 or more on the baseline total score of 20 or more on the Young Mania Rating Scale (YMRS; Young Young Mania Rating Scale (YMRS; Young et al et al, 1978) and a history of at least two , 1978) and a history of at least two manic or mixed episodes within the manic or mixed episodes within the previous 6 years. previous 6 years.
The trial consisted of four study The trial consisted of four study periods: screening (2-7 days); open-label periods: screening (2-7 days); open-label co-therapy (6-12 weeks); double-blind co-therapy (6-12 weeks); double-blind taper (4 weeks); and double-blind monotaper (4 weeks); and double-blind monotherapy (48 weeks). The starting daily therapy (48 weeks). The starting daily dosages for open-label co-therapy were dosages for open-label co-therapy were olanzapine 15 mg and lithium 600 mg. Subolanzapine 15 mg and lithium 600 mg. Subsequent dosages of olanzapine could range sequent dosages of olanzapine could range from 5 mg to 20 mg per day. Investigators from 5 mg to 20 mg per day. Investigators were required to optimise lithium dosage were required to optimise lithium dosage and reach a target serum level of 0.6-and reach a target serum level of 0.6-1.2 mmol/l by week 4 during this period. 1.2 mmol/l by week 4 during this period.
Patients who met symptomatic remisPatients who met symptomatic remission criteria for bipolar disorder -a total sion criteria for bipolar disorder -a total YMRS score of 12 or below and a total YMRS score of 12 or below and a total score of 8 or below on the 21-item score of 8 or below on the 21-item Hamilton Rating Scale for Depression Hamilton Rating Scale for Depression (HRSD; Hamilton, 1959) -during the (HRSD; Hamilton, 1959) -during the second study period (co-therapy) were second study period (co-therapy) were randomly assigned to treatment with either randomly assigned to treatment with either olanzapine or lithium monotherapy. olanzapine or lithium monotherapy. During the third study period, patients During the third study period, patients remained on their current dosage of remained on their current dosage of randomised treatment and the dosage of randomised treatment and the dosage of the discontinued drug was tapered over the discontinued drug was tapered over 4 weeks. During the final study period, 4 weeks. During the final study period, lithium levels were monitored and the lithium levels were monitored and the dosage adjusted to maintain serum levels dosage adjusted to maintain serum levels in the therapeutic range 0.6-1.2 mmol/l. in the therapeutic range 0.6-1.2 mmol/l. All patients randomly assigned to olanzaAll patients randomly assigned to olanzapine also had blood drawn to maintain pine also had blood drawn to maintain the study masking. For every outlier report the study masking. For every outlier report generated for a patient in the lithium group, generated for a patient in the lithium group, a sham lithium outlier report was sent to a a sham lithium outlier report was sent to a patient in the olanzapine group. Thus, repatient in the olanzapine group. Thus, reports to investigative sites indicating that ports to investigative sites indicating that the lithium dosage should be adjusted did the lithium dosage should be adjusted did not unmask the randomised assignment. not unmask the randomised assignment. Illness severity was assessed using the Illness severity was assessed using the YMRS and HRSD. YMRS and HRSD. The categorical defini-
The categorical definitions of euthymia, sub-syndromal symptions of euthymia, sub-syndromal symptoms and relapse ( 
Statistical methods Statistical methods
Stepwise logistic regression models were Stepwise logistic regression models were used to identify factors that were significant used to identify factors that were significant predictors of the proportion of time spent predictors of the proportion of time spent with sub-syndromal symptoms. The with sub-syndromal symptoms. The response, percentage time spent with subresponse, percentage time spent with subsyndromal symptoms, was broken into five syndromal symptoms, was broken into five categories by quartiles: 0%, 0-categories by quartiles: 0%, 0-5 525%, 25%, 25%-25%-5 550%, 50%-50%, 50%-5 575% and 75% or 75% and 75% or more. Linear logistic regression models for more. Linear logistic regression models for these ordinal response data were fitted by these ordinal response data were fitted by the method of maximum likelihood using the method of maximum likelihood using SAS (version 8.2) PROC LOGISTIC. Cate-SAS (version 8.2) PROC LOGISTIC. Categorical explanatory variables included thergorical explanatory variables included therapy, gender, index episode type (mania or apy, gender, index episode type (mania or mixed), mixed), presence of psychotic features, presence of psychotic features, rapidrapid-cycling status, proneness to deprescycling status, proneness to depression or mania (defined by the predominant sion or mania (defined by the predominant episode type in previous episodes), number episode type in previous episodes), number of previous bipolar episodes (0-5, 6-9, 10 of previous bipolar episodes (0-5, 6-9, 10 or more), number of previous manic epior more), number of previous manic episodes (0-2, 3-5, 6 or more) and number sodes (0-2, 3-5, 6 or more) and number of previous depressive episodes (0-1, 2-3, of previous depressive episodes (0-1, 2-3, 4 or more). Dimensional explanatory vari-4 or more). Dimensional explanatory variables included age, onset age, duration of ables included age, onset age, duration of illness, baseline YMRS total score, and illness, baseline YMRS total score, and baseline HRSD total score. The variable baseline HRSD total score. The variable therapy was included in all models regardtherapy was included in all models regardless of statistical significance. The other less of statistical significance. The other explanatory variables were entered into explanatory variables were entered into the model if they were significant at the the model if they were significant at the a a¼0.05 level and could be removed in a 0.05 level and could be removed in a stepwise manner if the least significant stepwise manner if the least significant effect in the model at a particular step did effect in the model at a particular step did not meet this level of significance for not meet this level of significance for staying in the model. Odds ratio estimates staying in the model. Odds ratio estimates and their corresponding 95% confidence and their corresponding 95% confidence intervals were calculated for explanatory intervals were calculated for explanatory variables in the final model. variables in the final model.
The presence of subThe presence of sub-syndromal sympsyndromal symptoms toms during the first 8 weeks was examined during the first 8 weeks was examined as a predictor of subsequent relapse. Sepaas a predictor of subsequent relapse. Separate analyses were made for each type of rate analyses were made for each type of sub-syndromal status (any episode, depressub-syndromal status (any episode, depressive, manic) and each type of relapse (any sive, manic) and each type of relapse (any episode, depressive, manic). Patients who episode, depressive, manic). Patients who completed at least 8 weeks of therapy withcompleted at least 8 weeks of therapy without relapse ( out relapse (n n¼340) were included in the 340) were included in the analysis. Additional analyses evaluated the analysis. Additional analyses evaluated the potential impact of the presence of residual potential impact of the presence of residual symptoms at the outset of the double-blind symptoms at the outset of the double-blind treatment phase and of the absence of treatment phase and of the absence of symptoms at the initiation of the doublesymptoms at the initiation of the doubleblind period blind period followed by the emergence followed by the emergence of subof sub-syndromal symptoms during the syndromal symptoms during the first 8 weeks on the subsequent risk of refirst 8 weeks on the subsequent risk of relapse: patients were stratified according to lapse: patients were stratified according to the presence (YMRS score 9-14) or absence the presence (YMRS score 9-14) or absence (YMRS score (YMRS score 4 48) of residual symptoms at 8) of residual symptoms at the outset of the double-blind period. Fishthe outset of the double-blind period. Fisher's exact test was used to test proportions, er's exact test was used to test proportions, and relapse incidence rates were characand relapse incidence rates were characterised by an estimate of the relative risk terised by an estimate of the relative risk with 95% confidence limits; estimates were with 95% confidence limits; estimates were constructed with patients having no time constructed with patients having no time with sub-syndromal symptoms during the with sub-syndromal symptoms during the first 8 weeks as the referent. first 8 weeks as the referent.
RESULTS RESULTS
Our analyses included 424 patients with Our analyses included 424 patients with bipolar I disorder. Their baseline demobipolar I disorder. Their baseline demographic and illness characteristics are graphic and illness characteristics are presented in Table 2 . No statistically signifpresented in Table 2 . No statistically significant difference was observed between the icant difference was observed between the olanzapine and lithium treatment groups olanzapine and lithium treatment groups on these baseline measures. on these baseline measures.
The percentages of patients with subThe percentages of patients with subsyndromal symptoms at any time during syndromal symptoms at any time during the 48-week study are shown in Table 3 . the 48-week study are shown in Table 3 . Presented in Table 4 are the percentages Presented in Table 4 are the percentages of time spent with sub-syndromal sympof time spent with sub-syndromal symptoms categorised by quartiles. There was toms categorised by quartiles. There was no statistically significant difference beno statistically significant difference between therapies with respect to percentage tween therapies with respect to percentage of patients with sub-syndromal symptoms of patients with sub-syndromal symptoms at any time, or the percentage of time with at any time, or the percentage of time with sub-syndromal bipolar symptoms overall or sub-syndromal bipolar symptoms overall or in the individual poles (depression or in the individual poles (depression or mania). The mean percentages of time mania Among patients who completed the Among patients who completed the first 8 weeks of the relapse prevention first 8 weeks of the relapse prevention phase without a major affective episode phase without a major affective episode ( (n n¼340), the subsequent rate of relapse 340), the subsequent rate of relapse for those with bipolar sub-syndromal for those with bipolar sub-syndromal symptoms was 36.8% (32 of 87) and symptoms was 36.8% (32 of 87) and 29.6% (75 of 253) for those without. 29.6% (75 of 253) for those without. Regardless of therapy, the presence of Regardless of therapy, the presence of sub-syndromal bipolar symptoms signifisub-syndromal bipolar symptoms significantly increased the likelihood of relapse cantly increased the likelihood of relapse into the depressive pole (17 of 87 patients into the depressive pole (17 of 87 patients with sub-syndromal bipolar symptoms with sub-syndromal bipolar symptoms v. v. 26 of 253 patients without such symptoms; 26 of 253 patients without such symptoms; relative risk 1.9, 95% CI 1.09-3.33, relative risk 1.9, 95% CI 1.09-3.33, P P¼0.038). The presence of sub-syndromal 0.038). 
DISCUSSION DISCUSSION
Our analyses identified illness characterisOur analyses identified illness characteristics that were associated with a greater tics that were associated with a greater amount of time spent experiencing subamount of time spent experiencing subsyndromal symptoms in patients with bisyndromal symptoms in patients with bipolar I disorder, and examined the impact polar I disorder, and examined the impact of these symptoms on outcomes. There of these symptoms on outcomes. There was no statistically significant difference was no statistically significant difference between the olanzapine and lithium treatbetween the olanzapine and lithium treatment groups with regard to the percentage ment groups with regard to the percentage of patients who experienced sub-syndromal of patients who experienced sub-syndromal symptoms or in the percentage of time symptoms or in the percentage of time spent with symptoms. Approximately spent with symptoms. Approximately 38% of patients experienced symptoms 38% of patients experienced symptoms that fell within the sub-syndromal range that fell within the sub-syndromal range of severity, as defined by rating scales, at of severity, as defined by rating scales, at any time during the maintenance phase of any time during the maintenance phase of this study. Among these patients, just over this study. Among these patients, just over a quarter (27%) of the time was spent with a quarter (27%) of the time was spent with sub-syndromal symptoms. These results are sub-syndromal symptoms. These results are consistent with previous reports from consistent with previous reports from non-controlled studies documenting the non-controlled studies documenting the prevalence of sub-syndromal symptoms in prevalence of sub-syndromal symptoms in patients with bipolar I disorder (Keitner patients with bipolar I disorder (Keitner et et al al, 1996; Judd , 1996; Judd et al et al, 2002; Post , 2002; Post et al et al, , 2003) . Our findings further extend the view 2003). Our findings further extend the view that sub-syndromal symptoms are common that sub-syndromal symptoms are common and pervasive in bipolar I disorder, even in and pervasive in bipolar I disorder, even in a population of patients who achieved a population of patients who achieved clinical response from an acute manic or clinical response from an acute manic or mixed episode and continued to receive mixed episode and continued to receive treatment for relapse prevention. treatment for relapse prevention.
Meaningful comparisons between these Meaningful comparisons between these findings and those of previous reports findings and those of previous reports 517 517 13.5 (9.9) 13.5 (9.9) 13.3 (10. with respect to time with sub-syndromal with respect to time with sub-syndromal symptoms are difficult to make because of symptoms are difficult to make because of differences in defining criteria, methods of differences in defining criteria, methods of assessment and study design. Notably, for assessment and study design. Notably, for participants in our study who experienced participants in our study who experienced relapse into an affective episode during relapse into an affective episode during the study period, only data prior to the the study period, only data prior to the event were included in the analyses. It event were included in the analyses. It should also be noted that all patients enshould also be noted that all patients entered this study with an index manic or tered this study with an index manic or mixed episode, which may account in part mixed episode, which may account in part for differences in the distribution of time for differences in the distribution of time with symptoms in the two poles relative with symptoms in the two poles relative to studies that involved patients with either to studies that involved patients with either manic/mixed or depressive episodes. Inmanic/mixed or depressive episodes. Indeed, previous studies have reported that deed, previous studies have reported that patients spend substantially more time with patients spend substantially more time with depressive symptoms than with manic depressive symptoms than with manic symptoms (Judd symptoms (Judd et al et al, 2002; Post , 2002; Post et al et al, , 2003; Joffe 2003; Joffe et al et al, 2004) , whereas the distri-, 2004), whereas the distribution of time with symptoms in our study bution of time with symptoms in our study was roughly equal for the manic (26.8%) was roughly equal for the manic (26.8%) and depressive (24.4%) poles. Since the and depressive (24.4%) poles. Since the polarity of index mood episode is a predicpolarity of index mood episode is a predictor of the polarity of subsequent relapse tor of the polarity of subsequent relapse (Tohen (Tohen et al et al, 2003) , it is possible that the , 2003), it is possible that the distribution of sub-syndromal symptoms is distribution of sub-syndromal symptoms is similarly dependent on the polarity of the similarly dependent on the polarity of the index episode. index episode.
Predictors of sub-syndromal Predictors of sub-syndromal symptoms symptoms
Of the clinical variables analysed, the preOf the clinical variables analysed, the presence of psychotic features and the sence of psychotic features and the number of previous depressive episodes number of previous depressive episodes were associated with increased time spent were associated with increased time spent with sub-syndromal symptoms. Patients with sub-syndromal symptoms. Patients who entered the study with psychotic who entered the study with psychotic features were more likely to experience features were more likely to experience a greater percentage of time with suba greater percentage of time with subsyndromal depressive symptoms than those syndromal depressive symptoms than those without such features. This finding is interwithout such features. This finding is interesting in light of recent reports questioning esting in light of recent reports questioning the prognostic value of psychotic features in the prognostic value of psychotic features in bipolar disorder with respect to illness bipolar disorder with respect to illness severity and treatment response (Keck severity and treatment response (Keck et et al al, 2003) . In a study by Swann , 2003) . In a study by Swann et al et al (2004) the presence of psychotic features (2004) the presence of psychotic features was associated with greater overall funcwas associated with greater overall functional impairment, but was not correlated tional impairment, but was not correlated with higher baseline mania scores or altered with higher baseline mania scores or altered treatment response. On the other hand, a treatment response. On the other hand, a study by Tohen study by Tohen et al et al (1990 Tohen et al et al ( (1990b identified ) identified the presence of psychotic features during the presence of psychotic features during the index episode as a predictor of shorter the index episode as a predictor of shorter time in remission. time in remission.
A greater number of previous depres-A greater number of previous depressive episodes was also associated with a sive episodes was also associated with a greater percentage of time spent with subgreater percentage of time spent with subsyndromal depressive symptoms, which is syndromal depressive symptoms, which is in accordance with a previous report by in accordance with a previous report by Post Post et al et al (2003) . These findings also extend (2003) . These findings also extend previous reports that a greater number of previous reports that a greater number of previous affective episodes increases the previous affective episodes increases the risk of subsequent relapse (Kessing risk of subsequent relapse (Kessing et al et al, , 2004) . 2004).
Predictors of relapse Predictors of relapse
In our study the presence of subIn our study the presence of sub-syndromal syndromal symptoms during the first 8 weeks of the symptoms during the first 8 weeks of the relapse prevention phase was associated relapse prevention phase was associated with a significantly greater likelihood of with a significantly greater likelihood of subsequent relapse, particularly into the subsequent relapse, particularly into the depressive pole. This finding agrees, in part, depressive pole. This finding agrees, in part, with previous studies that have reported an with previous studies that have reported an increased risk of relapse associated with increased risk of relapse associated with sub-syndromal symptoms (Goodnick sub-syndromal symptoms (Goodnick et al et al, , 1987; Tohen 1987; Tohen et al et al, 1990 Tohen et al et al, , 1990a Keller ; Keller et al et al, , 1992) . However, the presence of depressive 1992). However, the presence of depressive sub-syndromal symptoms was predictive of sub-syndromal symptoms was predictive of depressive relapse, whereas there was depressive relapse, whereas there was no corresponding relationship between no corresponding relationship between sub-syndromal manic symptoms and manic sub-syndromal manic symptoms and manic relapse. In contrast, in a study of relapse relapse. In contrast, in a study of relapse prevention with lithium, Keller prevention with lithium, Keller et al et al (1992) reported in a non-controlled study (1992) reported in a non-controlled study a stronger association between manic suba stronger association between manic subsyndromal symptoms and manic relapse resyndromal symptoms and manic relapse relative to the depressive polarity. It is not lative to the depressive polarity. It is not clear what factors account for these discreclear what factors account for these discrepant results; however, it is possible that the pant results; however, it is possible that the use of olanzapine and lithium in combinause of olanzapine and lithium in combination to treat the acute episode, and monotion to treat the acute episode, and monotherapy during relapse prevention, might therapy during relapse prevention, might have contributed to our results. Further have contributed to our results. Further analyses of sub-syndromal symptoms duranalyses of sub-syndromal symptoms during the first 8 weeks of the monotherapy ing the first 8 weeks of the monotherapy phase that differentiated residual subphase that differentiated residual subsyndromal symptoms (i.e. symptoms from syndromal symptoms (i.e. symptoms from the index episode that had not resolved the index episode that had not resolved completely) from newly emerged subcompletely) from newly emerged subsyndromal symptoms yielded intriguing syndromal symptoms yielded intriguing results: the emergence of sub-syndromal results: the emergence of sub-syndromal symptoms (in particular sub-syndromal symptoms (in particular sub-syndromal depressive symptoms) was associated with depressive symptoms) was associated with significantly greater risk of subsequent significantly greater risk of subsequent relapse into the depressive pole, whereas relapse into the depressive pole, whereas the presence of residual symptoms was the presence of residual symptoms was not. This finding suggests that the longitunot. This finding suggests that the longitudinal assessment of symptom severity, as dinal assessment of symptom severity, as opposed to just cross-sectional assessment, opposed to just cross-sectional assessment, might better determine the risk of might better determine the risk of subsequent relapse. subsequent relapse.
Limitations Limitations
There are several limitations to these anaThere are several limitations to these analyses that warrant discussion. Patients in lyses that warrant discussion. Patients in this study were required to achieve remisthis study were required to achieve remission from an acute manic or mixed episode sion from an acute manic or mixed episode to be included in the relapse prevention to be included in the relapse prevention phase of the trial; thus, this population conphase of the trial; thus, this population consisted of patients who responded to comsisted of patients who responded to combined olanzapine and lithium treatment bined olanzapine and lithium treatment and who might not be representative of and who might not be representative of the general population of people with bithe general population of people with bipolar I disorder. A related limitation is that polar I disorder. A related limitation is that our results may not be generalised to paour results may not be generalised to patients who are unable or refuse to particitients who are unable or refuse to participate in clinical trials. It should be noted, pate in clinical trials. It should be noted, however, that in contrast to naturalistic however, that in contrast to naturalistic studies, the analyses of data from our studies, the analyses of data from our randomised clinical trial were adjusted randomised clinical trial were adjusted for pharmacological treatment. Another for pharmacological treatment. Another limitation is the relatively short follow-up limitation is the relatively short follow-up period of only 1 year, which may not period of only 1 year, which may not characterise the full longitudinal course of characterise the full longitudinal course of bipolar disorder. bipolar disorder.
Our findings provide prognostic value Our findings provide prognostic value in terms of identifying patients at increased in terms of identifying patients at increased risk of affective relapse. Given that the risk of affective relapse. Given that the presence of sub-syndromal symptoms is presence of sub-syndromal symptoms is 51 8 51 8 
